About Us

Pioneering the Next Generation of Antiviral Therapeutics

Presidio Pharmaceuticals, Inc. is a San Francisco-based clinical stage specialty pharmaceutical company dedicated to the discovery and development of small-molecule antiviral therapeutics. Presidio has raised over $63 million in financing from Panorama Capital, Baker Brothers Investments, Bay City Capital, Ventures West, New Leaf Venture Partners, Nexus Medical Partners, Emerge Capital, and Sagamore Bioventures LLC.

Presidio’s current focus is HCV, where we have a pipeline comprised of two main programs (see Programs & Pipeline for more details). Presidio's main focus is on their HCV NS5A inhibitor program, which is currently undergoing clinical studies and is well positioned to compete in the growing HCV therapy market. The drug, PPI-668, is effective in vitro against the seven identified HCV viral genotypes, and is predicted to have once daily dosing regimen in man. Clinical proof of concept for the NS5A inhibitor is anticipated in the second quarter of 2012.

If you have questions about Presidio, please contact us.

	Management \| Board of Directors
	About Us Pioneering the Next Generation of Antiviral Therapeutics Presidio Pharmaceuticals, Inc. is a San Francisco-based clinical stage specialty pharmaceutical company dedicated to the discovery and development of small-molecule antiviral therapeutics. Presidio has raised over $63 million in financing from Panorama Capital, Baker Brothers Investments, Bay City Capital, Ventures West, New Leaf Venture Partners, Nexus Medical Partners, Emerge Capital, and Sagamore Bioventures LLC. Presidio’s current focus is HCV, where we have a pipeline comprised of two main programs (see Programs & Pipeline for more details). Presidio's main focus is on their HCV NS5A inhibitor program, which is currently undergoing clinical studies and is well positioned to compete in the growing HCV therapy market. The drug, PPI-668, is effective in vitro against the seven identified HCV viral genotypes, and is predicted to have once daily dosing regimen in man. Clinical proof of concept for the NS5A inhibitor is anticipated in the second quarter of 2012. If you have questions about Presidio, please contact us. Presidio Pharmaceuticals, Inc.